A CASE SERIES OF ADENOMATOID ODONTOGENIC TUMOR: CLINICOPATHOLOGIC AND MOLECULAR CHARACTERIZATION

Abstract

Listen

Translate article

We report a series of 22 adenomatoid odontogenic tumors (AOTs). The patients' age, tumor location, association with impacted teeth, and clinical size were obtained. Capsule thickness was evaluated. The patients’ mean age was 18.8 years (range 6-57 y). Considering the cases with known information, 16 occurred in women and 5 in men, 11 in the maxilla, and 10 in the mandible, 13 in the anterior regions, and 7 in the posterior regions, 8 in association with impacted teeth, and 9 not associated with impaction. We evaluated 3 AOT samples for mutations in a panel of 50 oncogenes and tumor suppressor genes by next-generation sequencing. The KRAS G12V mutation was detected in 3 samples. We screened the other 19 samples for KRAS codon 12 mutations. KRAS codon 12 mutations occurred in 15 out of 22 (68%), KRAS G12V in 14 out of 22 cases, and KRAS G12R in 1 out of 22. Codon 12 mutations were not associated with any of the clinicopathologic parameters tested (P > .05). Supported by FAPEMIG/CAPES/CNPq/Brazil. We report a series of 22 adenomatoid odontogenic tumors (AOTs). The patients' age, tumor location, association with impacted teeth, and clinical size were obtained. Capsule thickness was evaluated. The patients’ mean age was 18.8 years (range 6-57 y). Considering the cases with known information, 16 occurred in women and 5 in men, 11 in the maxilla, and 10 in the mandible, 13 in the anterior regions, and 7 in the posterior regions, 8 in association with impacted teeth, and 9 not associated with impaction. We evaluated 3 AOT samples for mutations in a panel of 50 oncogenes and tumor suppressor genes by next-generation sequencing. The KRAS G12V mutation was detected in 3 samples. We screened the other 19 samples for KRAS codon 12 mutations. KRAS codon 12 mutations occurred in 15 out of 22 (68%), KRAS G12V in 14 out of 22 cases, and KRAS G12R in 1 out of 22. Codon 12 mutations were not associated with any of the clinicopathologic parameters tested (P > .05). Supported by FAPEMIG/CAPES/CNPq/Brazil.